Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.75 |
| ▸ | CA12 | O43570 | 4/20 | 0.70 |
| ▸ | CA9 | Q16790 | 4/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004806 | 0.86 | EPHX2 (0.75) | EPHX2CA12CA9CA1CA2 | |
| SCHEMBL4003310 | 0.84 | EPHX2 (0.67) | EPHX2CA12CA9CA1CA2 | |
| SCHEMBL4001878 | 0.84 | EPHX2 (0.71) | EPHX2CA12CA9CA1CA2 | |
| SCHEMBL4001107 | 0.84 | EPHX2 (0.74) | EPHX2CA12CA9CA1CA2 | |
| SCHEMBL4001763 | 0.82 | EPHX2 (0.68) | EPHX2CA12CA9CA1CA2 | |
| SCHEMBL12932185 | 0.81 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL13454387 | 0.80 | CA9 (1.00) | CA12CA9CA1CA2POLB | |
| SCHEMBL25684474 | 0.80 | EPHX2 (0.84) | EPHX2 | |
| SCHEMBL14220983 | 0.80 | CA12 (0.50) | EPHX2CA12CA9CA1CA2 | |
| SCHEMBL1420838 | 0.79 | EPHX2 (1.00) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2068857-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2008040000-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CA12 1772/4885CA9 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.